181 related articles for article (PubMed ID: 34497362)
1. Molecular classification of follicular thyroid carcinoma based on TERT promoter mutations.
Park H; Shin HC; Yang H; Heo J; Ki CS; Kim HS; Kim JH; Hahn SY; Chung YJ; Kim SW; Chung JH; Oh YL; Kim TH
Mod Pathol; 2022 Feb; 35(2):186-192. PubMed ID: 34497362
[TBL] [Abstract][Full Text] [Related]
2. Association of Ultrasonography Features of Follicular Thyroid Carcinoma With Tumor Invasiveness and Prognosis Based on WHO Classification and TERT Promoter Mutation.
Kim MK; Park H; Oh YL; Shin JH; Kim TH; Hahn SY
Korean J Radiol; 2024 Jan; 25(1):103-112. PubMed ID: 38184773
[TBL] [Abstract][Full Text] [Related]
3. Selection Criteria for Completion Thyroidectomy in Follicular Thyroid Carcinoma Using Primary Tumor Size and TERT Promoter Mutational Status.
Park H; Heo J; Ki CS; Shin JH; Oh YL; Son YI; Kim JS; Kim SW; Chung JH; Kim TY; Kim TH; Kim JH
Ann Surg Oncol; 2023 May; 30(5):2916-2925. PubMed ID: 36637642
[TBL] [Abstract][Full Text] [Related]
4. Clinical Implication of World Health Organization Classification in Patients with Follicular Thyroid Carcinoma in South Korea: A Multicenter Cohort Study.
Jin M; Kim ES; Kim BH; Kim HK; Yi HS; Jeon MJ; Kim TY; Kang HC; Kim WB; Shong YK; Kim M; Kim WG
Endocrinol Metab (Seoul); 2020 Sep; 35(3):618-627. PubMed ID: 32981304
[TBL] [Abstract][Full Text] [Related]
5. TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer.
Liu X; Qu S; Liu R; Sheng C; Shi X; Zhu G; Murugan AK; Guan H; Yu H; Wang Y; Sun H; Shan Z; Teng W; Xing M
J Clin Endocrinol Metab; 2014 Jun; 99(6):E1130-6. PubMed ID: 24617711
[TBL] [Abstract][Full Text] [Related]
6. Mutation profiles of follicular thyroid tumors by targeted sequencing.
Duan H; Liu X; Ren X; Zhang H; Wu H; Liang Z
Diagn Pathol; 2019 May; 14(1):39. PubMed ID: 31077238
[TBL] [Abstract][Full Text] [Related]
7. Follicular and Hurthle Cell Carcinoma: Comparison of Clinicopathological Features and Clinical Outcomes.
Matsuura D; Yuan A; Wang L; Ranganath R; Adilbay D; Harries V; Patel S; Tuttle M; Xu B; Ghossein R; Ganly I
Thyroid; 2022 Mar; 32(3):245-254. PubMed ID: 35078345
[No Abstract] [Full Text] [Related]
8. Changes in the clinicopathological characteristics and genetic alterations of follicular thyroid cancer.
Song YS; Lim JA; Min HS; Kim MJ; Choi HS; Cho SW; Moon JH; Yi KH; Park DJ; Cho BY; Park YJ
Eur J Endocrinol; 2017 Dec; 177(6):465-473. PubMed ID: 28864536
[TBL] [Abstract][Full Text] [Related]
9. 5hmC Immunohistochemistry: A Predictor of
Hysek M; Hellgren SL; Condello V; Xu Y; Larsson C; Zedenius J; Juhlin CC
J Histochem Cytochem; 2023 Aug; 71(8):451-458. PubMed ID: 37486076
[TBL] [Abstract][Full Text] [Related]
10. Refining Dynamic Risk Stratification and Prognostic Groups for Differentiated Thyroid Cancer With TERT Promoter Mutations.
Kim TH; Ki CS; Kim HS; Kim K; Choe JH; Kim JH; Kim JS; Oh YL; Hahn SY; Shin JH; Jang HW; Kim SW; Chung JH
J Clin Endocrinol Metab; 2017 May; 102(5):1757-1764. PubMed ID: 28323925
[TBL] [Abstract][Full Text] [Related]
11. The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas.
Liu T; Wang N; Cao J; Sofiadis A; Dinets A; Zedenius J; Larsson C; Xu D
Oncogene; 2014 Oct; 33(42):4978-84. PubMed ID: 24141777
[TBL] [Abstract][Full Text] [Related]
12. TERT Promoter Mutation Spatial Heterogeneity in a Metastatic Follicular Thyroid Carcinoma: Implications for Clinical Work-Up.
Stenman A; Hysek M; Jatta K; Bränström R; Darai-Ramqvist E; Paulsson JO; Wang N; Larsson C; Zedenius J; Juhlin CC
Endocr Pathol; 2019 Sep; 30(3):246-248. PubMed ID: 31154561
[TBL] [Abstract][Full Text] [Related]
13. Follicular thyroid carcinoma: the role of histology and staging systems in predicting survival.
Lo CY; Chan WF; Lam KY; Wan KY
Ann Surg; 2005 Nov; 242(5):708-15. PubMed ID: 16244545
[TBL] [Abstract][Full Text] [Related]
14. TERT promoter mutations identify a high-risk group in metastasis-free advanced thyroid carcinoma.
Bournaud C; Descotes F; Decaussin-Petrucci M; Berthiller J; de la Fouchardière C; Giraudet AL; Bertholon-Gregoire M; Robinson P; Lifante JC; Lopez J; Borson-Chazot F
Eur J Cancer; 2019 Feb; 108():41-49. PubMed ID: 30648628
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes and implication of radioactive iodine therapy on cancer-specific survival in WHO classification of FTC.
Li G; Ye Z; Wei T; Zhu J; Li Z; Lei J
J Clin Endocrinol Metab; 2024 Mar; ():. PubMed ID: 38436929
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Significance of TERT Promoter Mutations in Papillary Thyroid Carcinomas in a BRAF(V600E) Mutation-Prevalent Population.
Lee SE; Hwang TS; Choi YL; Han HS; Kim WS; Jang MH; Kim SK; Yang JH
Thyroid; 2016 Jul; 26(7):901-10. PubMed ID: 27184112
[TBL] [Abstract][Full Text] [Related]
17. TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA.
Wang N; Liu T; Sofiadis A; Juhlin CC; Zedenius J; Höög A; Larsson C; Xu D
Cancer; 2014 Oct; 120(19):2965-79. PubMed ID: 24898513
[TBL] [Abstract][Full Text] [Related]
18. Association between TERT promoter mutations and clinical behaviors in differentiated thyroid carcinoma: a systematic review and meta-analysis.
Yang J; Gong Y; Yan S; Chen H; Qin S; Gong R
Endocrine; 2020 Jan; 67(1):44-57. PubMed ID: 31655978
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of patient age in minimally and widely invasive follicular thyroid carcinoma: investigation of three age groups.
Ito Y; Miyauchi A; Tomoda C; Hirokawa M; Kobayashi K; Miya A
Endocr J; 2014; 61(3):265-71. PubMed ID: 24390055
[TBL] [Abstract][Full Text] [Related]
20. Effect of single-nucleotide polymorphism in TERT promoter on follicular thyroid tumor development.
Hirokawa T; Arimasu Y; Nakazato Y; Chiba T; Fujiwara M; Kamma H
Pathol Int; 2020 Apr; 70(4):210-216. PubMed ID: 31943533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
